What happened with CMPS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
COMPASS Pathways is a clinical-stage biotechnology company focused on depression that has not responded adequately to existing treatments. Its only treatment candidate in clinical development, COMP360, contains a proprietary formulation of psilocybin and is in Phase 3 trials for treatment-resistant depression. The company is also developing it for post-traumatic stress disorder. It has no approved treatment or revenue and funds development through share issues and borrowing.
If COMP360 is approved, the company plans to sell it to public and private healthcare providers and clinic networks in the United States using its own sales team. Third-party treatment sites would administer it, with specially trained healthcare professionals supporting and monitoring patients before, during and after treatment. Sales would depend on enough sites and trained staff being available, as well as insurance coverage and reimbursement that make treatment affordable and viable for providers.
The business rests on COMP360 completing development and gaining approval. In the United States, psilocybin is a Schedule I controlled substance, so commercial sales also require federal and state scheduling changes. COMPASS Pathways outsources drug manufacturing and currently relies on a single supplier for the active ingredient, although it has identified backup manufacturers.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
COMPASS Pathways' prospects hinge on COMP360 succeeding in trials and winning approval, while nonprofit Usona Institute's Phase 3 psilocybin program could challenge its eventual pricing and uptake.
GH Research PLC and COMPASS Pathways are developing tryptamine-based drugs for treatment-resistant depression, putting them in competition for the same patients and treatment clinics. If approved, GH Research plans to market its treatments to healthcare providers, clinic networks and payors in the United States and major European markets.
Helus Pharma Inc. and COMPASS Pathways are advancing late-stage psilocybin-related depression treatments that could compete for patients and prescribing clinicians. Watch Helus's Phase 3 trials in major depressive disorder, where its treatment is used alongside other therapy, rather than COMP360's initial focus on treatment-resistant depression.
Definium Therapeutics, Inc.'s Phase 3 lysergide treatment for major depressive disorder could compete with COMPASS Pathways' COMP360 in psychedelic depression care. Watch the depression results for DT120 ODT; it is still investigational, and U.S. prescribing would require controlled-substance rescheduling after FDA approval.
Axsome Therapeutics, Inc already sells AUVELITY for major depressive disorder in the United States, competing for depression-care spending that COMPASS Pathways hopes to reach with COMP360. AUVELITY sales are the relevant line to watch, rather than Axsome's combined revenue from depression, sleepiness and migraine drugs.
Johnson & Johnson's Janssen already markets Spravato for treatment-resistant depression, giving COMPASS Pathways' COMP360 an established drug alternative to compete against if approved. Spravato's position with these patients matters more to this comparison than Johnson & Johnson's broader prescription-medicine business.
Neuronetics, Inc. competes with COMP360 through magnetic-stimulation treatments and its Greenbrook clinics' Spravato care, but Greenbrook also works with COMPASS Pathways to research how COMP360 could be delivered if FDA-approved. Watch that delivery research: Neuronetics earns most of its revenue from clinic services and recurring treatment sessions.
Alto Neuroscience Inc. is developing drugs for treatment-resistant and major depressive disorder that could compete with COMPASS Pathways' COMP360 for depression patients. Watch whether its clinical results support its approach of using patient tests and biological markers to identify people likely to respond.
Neumora Therapeutics, Inc. is developing navacaprant for depression, making it a potential rival to COMPASS Pathways in the future market for new antidepressant treatments.
Xenon Pharmaceuticals Inc's Phase 3 azetukalner program for major depressive disorder could offer depression patients another option alongside COMPASS Pathways' prospective COMP360. Watch its depression trial results rather than revenue: azetukalner remains investigational, and Xenon's revenue to date comes from collaborations and licensing, not product sales.
Fed Interest Rate Decision
The Fed’s decision on its benchmark interest rate matters to COMPASS Pathways because a higher prime rate can raise the interest it pays each month on its Hercules loan.
Expected4.0%Last release4.0%
If it comes in above expectations
If rates rise more than expected, prime may rise and increase COMPASS Pathways’ monthly interest costs when the prime-based loan rate applies.
If it comes in below expectations
If rates fall more than expected, prime may fall and reduce COMPASS Pathways’ monthly interest costs when the prime-based loan rate applies.
COMPASS Pathways Plc earningsThis company
COMPASS Pathways has no approved product or sales, so its report shows how much cash advancing COMP360 takes and how long its funding can support development.
Read cash used in operations alongside cash on hand. Steady cash use with a substantial balance would leave COMPASS Pathways more room to advance clinical and regulatory work; faster cash use and a thinner balance would increase pressure to raise funds or cut spending, potentially slowing COMP360 development.
